This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The National Academies of Sciences, Engineering, and Medicine recently released a congressionally mandated report on how to make amyotrophic lateral sclerosis — a brutal, always fatal condition — a “livable” disease in the next 10 years. Essentially, the committee was tasked with delivering a plan for a moonshot. As a health care innovation expert and someone living with ALS, I have to say that the report barely gets off the ground.
With this med review, I’m simply looking at a medication list to help formulate ideas to investigate. I’ll focus heavily on my concern for using an NSAID in this patient. NSAID and Heart Failure Concerns There are a few issues of note with the cardiac/heart failure medication regimen. I always have the prescribing cascade in […] The post NSAID Problems – Polypharmacy Case Study appeared first on Med Ed 101.
A few years ago, the Centers for Medicare and Medicaid Services launched a big experiment. The agency wanted to see if financial incentives and penalties would improve care for people with end-stage kidney disease. So far, it hasn’t worked, a new study finds. The End-Stage Renal Disease Treatment Choices (ETC) model is a historic effort, both because it’s the largest such experiment in the history of American health care and because, unlike previous CMS Innovation Center pilot prog
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
This chart shows the pharmaceutical companies with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
We can build anything at Pharmacy Mentor. We were very excited about the prospect of launching an aesthetics pharmacy clinic, which we knew would be a market-leading contender About This Pharmacy Skin On You is a B2B aesthetics pharmacy specialising in dermal filler products and delivering top-notch quality aesthetics products to practitioners at very competitive market prices.
We can build anything at Pharmacy Mentor. We were very excited about the prospect of launching an aesthetics pharmacy clinic, which we knew would be a market-leading contender About This Pharmacy Skin On You is a B2B aesthetics pharmacy specialising in dermal filler products and delivering top-notch quality aesthetics products to practitioners at very competitive market prices.
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
In this episode, I’ll discuss an article about which vasopressor is best in early traumatic brain injury patients. Episode 935: What vasopressor is best to use in traumatic brain injury? Subscribe on iTunes , Android , or Stitcher Patients who have severe traumatic brain injury and develop hypotension that requires vasopressor therapy are already at risk for mortality and poor long term outcomes.
GEP ACQUIRES OPUSCAPITA Vijendra Mon, 07/01/2024 - 09:43 Leading Europe-Based E-Invoicing Provider Expands GEP Leadership Across the Nordic Countries Learn More Asset type Newsroom Banner Slide Title GEP Acquires OpusCapita Mobile Banner Image Top Banner
RAPS Convergence 2024 is set to host a must-attend session on CDRH’s Total Product Life Cycle Advisory Program (TAP), promising attendees an exclusive insight into a pioneering initiative aimed at improving the medical device commercialization landscape. Session Details: A Path to Faster Breakthrough Device Commercialization – CDRH’s Total Product Life Cycle Advisory Program (TAP) Thursday, September 19, 2024, 4:30 PM – 5:30 PM Session Leader: Adrienne Lenz, RAC – Principal Medical Device Regula
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.
In the United States ( US), a recent initiative by major pharmaceutical companies to cap the cost of asthma inhalers at $35 per month marks a significant development in healthcare affordability and accessibility. Overall, the price cap on asthma inhalers represents a multifaceted victory. For patients, it means improved access to life-saving medications and a reduction in financial stress.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
328 
Let's personalize your content